This study is undertaken to investigate the clinical effecte of Neutrogin(recornbinant human granulocyte-colony stimulatiing factor) in 25 patients with ovarian caneer who received two courses of CAP chemotherapy. In the first courae of chemotherapy as a contml course, all patients were treated with CAP chemotherapy alone and during the second course, Neutrogin was given at a dose of 2ug/kg/day subcutaneouely for 14 days 24 hours after completion of chemotherapy. Neutrogin significantly increaaed the nadir count of leukocyte and abaolute neutrophil and decreased tbe number of days per patient on which the absolute neutrophil count was 1,000/mm3 or less. The mean recovery time required for neutrophil to greater than l,500/mm3 after nadir were significantliy decreased in the seeond comse as compared with the first course. Each one patient exriened mild side effects of Neatrogin, such as fever, tene pain and malaise and rernovered without tretment. These results showed that Neutrogin is extremely effective and useful to treat chemotherapy indueed leukopenia and to accelerate the recovery from these complications.